- Home
- PSNL vs TIL Comparison
PSNL vs TIL Comparison
Compare PSNL & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- TIL
- Stock Information
- Founded
- PSNL 2011
- TIL 2018
- Country
- PSNL United States
- TIL United States
- Employees
- PSNL N/A
- TIL N/A
- Industry
- PSNL Medical Specialities
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- PSNL Health Care
- TIL Health Care
- Exchange
- PSNL Nasdaq
- TIL Nasdaq
- Market Cap
- PSNL 576.8M
- TIL 230.1M
- IPO Year
- PSNL 2019
- TIL 2021
- Fundamental
- Price
- PSNL $7.51
- TIL $23.81
- Analyst Decision
- PSNL Strong Buy
- TIL Buy
- Analyst Count
- PSNL 5
- TIL 5
- Target Price
- PSNL $8.00
- TIL $119.00
- AVG Volume (30 Days)
- PSNL 1.7M
- TIL 334.3K
- Earning Date
- PSNL 08-06-2025
- TIL 08-12-2025
- Dividend Yield
- PSNL N/A
- TIL N/A
- EPS Growth
- PSNL N/A
- TIL N/A
- EPS
- PSNL N/A
- TIL N/A
- Revenue
- PSNL $85,694,000.00
- TIL N/A
- Revenue This Year
- PSNL $0.45
- TIL N/A
- Revenue Next Year
- PSNL $25.75
- TIL N/A
- P/E Ratio
- PSNL N/A
- TIL N/A
- Revenue Growth
- PSNL 15.57
- TIL N/A
- 52 Week Low
- PSNL $1.17
- TIL $9.62
- 52 Week High
- PSNL $7.51
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- PSNL 78.68
- TIL 45.83
- Support Level
- PSNL $6.27
- TIL $20.60
- Resistance Level
- PSNL $7.03
- TIL $31.67
- Average True Range (ATR)
- PSNL 0.50
- TIL 3.53
- MACD
- PSNL 0.06
- TIL -1.54
- Stochastic Oscillator
- PSNL 99.17
- TIL 17.93
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.